VIVELLE
LOE ApproachingNDATRANSDERMALSYSTEM
Approved
Oct 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VIVELLE by Novartis is characteristics. First approved in 1994.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVELLE is an estradiol transdermal patch approved in 1994 for hormone replacement therapy in postmenopausal women. It delivers estradiol, the principal intracellular human estrogen, through the skin to modulate pituitary gonadotropin secretion and reduce symptoms of estrogen deficiency. The drug works by binding to nuclear estrogen receptors in responsive tissues to restore hormonal balance in postmenopausal patients.
LOE Approaching
Product is entering loss-of-exclusivity phase with moderate competitive pressure (30/100), indicating a contracting commercial team and focus shifting to line extensions or niche positioning.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VIVELLE offers limited career growth opportunity given its mature, LOE-approaching lifecycle and zero active job postings. Roles available focus on defensive commercial operations, managed care negotiations, and generic transition planning rather than growth initiatives.
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.